Epstein-Barr Virus Seropositivity, Immune Dysregulation, and Mortality in Pediatric Sepsis

Epstein-Barr virus (EBV) seropositivity is associated with chronic immune dysregulation conditions, including multiple sclerosis, systemic lupus erythematosus, post-COVID-19 condition, and multiple cancers. Sepsis is an acute immune dysregulation condition attributed to 1 of 5 global deaths. To assess causal associations among EBV seropositivity, immune dysregulation, and mortality in children with sepsis. This cohort study analyzed 320 children with sepsis in the 9-center Eunice Kennedy Shriver National Institutes of Child Health and Development Collaborative Pediatric Critical Care Research Network Phenotyping Pediatric Sepsis-Induced Multiple Organ Failure (PHENOMS) study who had not previously received intravenous immune globulin. Blood samples and clinical data were collected from January 1, 2015, to December 31, 2018, and assayed from January 1, 2019, to December 31, 2022. Causal algorithms were modeled in directed acyclic graphs and subsequent sensitivity and mediation analyses applied with further confirmation by structural equation modeling. Data analysis was performed from May 2022 to January 2025. Blood sample collected at 24 to 48 hours of sepsis. Circulating biomarkers of inflammation (C-reactive protein, ferritin, and 32 cytokines), immune depression (ex vivo tumor necrosis factor response to endotoxin < 200 pg/mL), thrombotic microangiopathy (ADAMTS13 activity <57%), and EBV seropositivity (viral capsid IgG) were measured. Causal inference analysis identified causal associations between EBV seropositivity, immune dysregulation biomarkers, macrophage activation syndrome, and death. Of the 320 children (median [IQR] age, 6 [1-12] years; 172 [53.8%] male), 150 (46.9%) were previously healthy, and 72 (22.5%) had immunocompromise at admission. A total of 172 (53.8%) had causal associations with death directly and through the mediators hyperferritinemia and macrophage activation syndrome (MAS) and also had direct causal associations with increased C-reactive protein, ferritin, and interleukin 18 binding protein, which in turn had direct causal associations with decreased ADAMTS 13 activity and decreased whole blood ex vivo tumor necrosis factor response to endotoxin. Mediation analysis found that EBV seropositivity was associated with mortality (estimate [SE], 1.86 [0.55]; P < .001). With both EBV seropositivity and ferritin included in the model, the effect of EBV seropositivity on death remained (estimate [SE], 1.52 [0.57]; P = .007), as did the ferritin effect (estimate [SE], 0.50 [0.15]; P = .001). EBV seropositivity remained significantly associated with death even after adjustment for MAS (estimate [SE], 1.78 [0.56]; P = .001). In this cohort study of pediatric sepsis, EBV seropositivity was associated with immune dysregulation and mortality. Further study is warranted to address the possibility that latent EBV infection immune reprogramming poses an important public health problem that contributes to not only chronic disorders of immune dysregulation but also acute disorders of immune dysregulation, such as sepsis.